Medical/Pharmaceuticals
Ascentage Pharma's First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation
SUZHOU, China and ROCKVILLE, Md., March 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Ev...
2021-03-24 19:07
2644
LimaCorporate And HSS Partner To Open First Provider-based Design And 3D Printing Center For Complex Joint Reconstruction Surgery
SAN DANIELE DEL FRIULI, Italy, March 24, 2021 /PRNewswire/ -- LimaCorporate
2021-03-24 16:00
2608
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate
* Over 22,000 participants aged 18 years or older are expected to be enrolled in SPECTRA acrossLatin America, Asia, Europe and Africa * Interim analysis of the primary endpoint expected in the middle of 2021 CHENGDU, China and EMERYVILLE, Calif., March 24, 2021 /PRNewswire/ -- Clover Biopharm...
2021-03-24 14:18
3747
Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson's disease with the US FDA
HONG KONG, March 23, 2021 /PRNewswire/ -- Forest Hills Partners Hong Kong Limited (also known as Forest Hills Lab) is ready to file an Investigative New Drug (IND) application with the US FDA inApril 2021 to assess tolerability and efficacy with one of its drug candidates, namely FHL-301 in a pha...
2021-03-24 12:25
5787
Mindray Releases New Ceiling Supply Unit, Creating a More Optimized ICU Environment
SHENZHEN, China, March 24, 2021 /PRNewswire/ -- Mindray (SZSE: 300760), a global leader in developing and providing medical devices, has released a new series of ceiling supply units which exceeds ISO 11197-2019 standards. The HyPort R80 is the newest generation of bedside device management syste...
2021-03-24 11:49
2871
CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients
* GAVRETO has been approved for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy * GAVRETO is the first approved selective RET inhibitor in China and first approved precision therapy for CStone SUZHOU,...
2021-03-24 10:46
5855
Transcenta Announces Appointments of Dr. Xichen Zhang as Senior Vice President of Manufacturing and Dr. Steven Yu as Senior Vice President of DMPK and Translational Science
SUZHOU, China, March 23, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), aclinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the expansion of its senior managem...
2021-03-24 08:00
1637
Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial
Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention. BAGSVÆRD, Denmark, March 24, 2021 /PRNewswire/ -- New results from the STEP phase 3a clinical trial p...
2021-03-24 04:41
1657
Dr. Cheng-Chi Chao joins ChemPartner as Vice President and Head of Immunotherapy and Inflammation
SHANGHAI, March 23, 2021 /PRNewswire/ -- Shanghai ChemPartner announced today the appointment of Cheng-Chi Chao, Ph.D. as Vice President and Head of Immunotherapy and Inflammation. Dr. Chao has over 20 years of experience in drug development and extensive expertise in the fields of immune-oncolo...
2021-03-24 00:02
3059
Alphamab Oncology Reports Full Year 2020 Financial Results and Business Highlights
SUZHOU, China, March 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), reported financial results for the full year ended December 31, 2020 and highlighted recent progress and upcoming milestones. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "2020 is amilestone ...
2021-03-23 23:08
4599
2020 Results Record High Despite a Challenging Year
Revenue Increased by 40.9% Y-o-Y to RMB5,612 Million Gross Profit Rose by 52.7% Y-o-Y to RMB2,533 Million Net Profit Grew by 67.5% Y-o-Y to RMB1,693 Million Record-high Gross Margin of 45.1% and Net Profit Margin of 30.2% Milestone Revenue Surged by 71.7% to US$95 Million Total Backlog up 122.0% to ...
2021-03-23 20:59
4568
Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data
RARITAN, N.J., March 23, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received authorization from the U.S. Food and Drug Administration to update key claims for the VITROS® SARS-CoV-2 Antige...
2021-03-23 20:00
3443
Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®
The company's proven ability to reduce symptoms of occasional depression with Affron®, and its strong focus on quality control, have helped it deliver a truly outstanding product LONDON, March 23, 2021 /PRNewswire/ -- Based on its recent analysis of the North American market for industrial enter...
2021-03-23 20:00
1625
Pharma Industry to Spend $4.5 Billion on Digital Transformation by 2030
While the creation, manufacture, and supply of COVID vaccines are grabbing attention, behind the scenes, pharma manufacturers are digitizing at pace LONDON, March 23, 2021 /PRNewswire/ -- Pharma 4.0 concepts are taking hold in pharmaceutical manufacturing. The industry's unique characteristics ar...
2021-03-23 16:00
1794
Diluent or Immuno-Reagent solutions for your diagnostic testing kits (Covid, Flu, etc.)
PARIS, March 23, 2021 /PRNewswire/ -- Unither Pharmaceuticals, the
Blow-Fill-Seal (BFS) worldwide leader, provides diagnostic companies with
capacity solutions and innovative technologies for their testing kits (Covid,
Flu, etc.).
2021-03-23 15:04
2901
Taiko Pharmaceutical Officially Launches "Cleverin" in Mexico, Top Made-in-Japan Brand for Removing Viruses/Bacteria, Deodorization
OSAKA, Japan, March 23, 2021 /PRNewswire/ -- Together with a local distribution partner, Torishi S.A. de C.V., Taiko Pharmaceutical Co., Ltd. (hereinafter Taiko), based inOsaka, Japan, has announced the launch of "Cleverin," a top made-in-Japan brand (*1) among products for removing viruses/bacte...
2021-03-23 14:00
4400
Shockwave Announces Joint Venture In China with Genesis MedTech Group
SINGAPORE, March 23, 2021 /PRNewswire/ -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company has signed an agreement to form a joint venture with Genesis MedTe...
2021-03-23 11:38
9913
Northern Sydney Cancer Centre Partners with Sun Nuclear as Newest SunCHECK™ Platform Reference Site
MELBOURNE, Fla., March 23, 2021 /PRNewswire/ -- Sun Nuclear Corporation announced today thatAustralia's Northern Sydney Cancer Centre (NSCC) is now a reference site for theSunCHECK™ Quality Management Platform. The Centre joins leading clinics worldwide already in the reference site program. Glob...
2021-03-23 03:51
1936
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Hungary
* Marks vaccine's first approval by an European Union member state, following Mexico, Pakistan and China * Continues to boost production capacity to meet increasing demand * Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions * 95.47% effectiv...
2021-03-23 00:43
4406
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences' Anti-PD-1
BOSTON and BEIJING, March 22, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab Injecti...
2021-03-22 22:30
2128
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 314 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
GIGABYTE Strengthens NVIDIA® Partnership to Drive Innovation in AI-Powered Gaming and Creative Solutions
2026-01-17 00:00
7299
GAC Energy Releases 2025 EV Charging Ecosystem Report: Over 23,000 Self-Operated Charging Piles Across China
2026-01-17 10:59
5823
